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a  b  s  t  r  a  c  t
Insulin  resistance  contributes  to the pathophysiology  of diabetes  and  is a  hallmark  of  obesity,  metabolic
syndrome,  and  many  cardiovascular  diseases.  Therefore,  quantifying  insulin  sensitivity/resistance  in
humans and  animal  models  is  of  great  importance.
Various methods  are  used  to  assess  insulin  sensitivity  both  in  individuals  and  in  study  populations.
Validity,  reproducibility,  cost,  and  degree  of  subject  burden  are  important  factors  for  both  clinicians  and
researchers  to consider  when  weighing  the merits  of  a particular  method.  Some  methods  rely  on  steady-
state  analysis  of  glucose  and  insulin,  whereas  others  rely  on  dynamic  testing.  Each  of  these  methods  has
distinct  advantages  and  limitations.  Thus,  optimal  choice  and employment  of a speciﬁc  method  depend
on the nature  of the  studies  being  performed.  Established  direct  methods  for measuring  insulin  sensi-
tivity  in  vivo  are  relatively  complex.  Finally,  simple  surrogate  indexes  for insulin  sensitivity/resistance
are  available  that are  derived  from  blood  insulin  and  glucose  concentrations  under  fasting  conditions
(steady  state)  or in the  postprandial  state  (dynamic).  This article  highlight  merits,  limitations,  and  appro-
priate  use  of  current  in  vivo  measures  of insulin  sensitivity/resistance  and  presents  the  advantages  and
disadvantages  of  each.
©  2012  Sociedade  Portuguesa  de  Endocrinologia,  Diabetes  e Metabolismo.  Published  by  Elsevier
España,  S.L.  All  rights  reserved.
Métodos  de  avaliac¸ ão  e  índices  de  sensibilidade  à  insulina
alavras-chave:
lamp de glucose hiperinsulinémico
 euglicémico
este oral de tolerância à glucose
este de tolerância à refeic¸ ão
este rápido de sensibilidade à insulina
valiac¸ ão do modelo de homeostase
lucose oral e sensibilidade à insulina
r  e  s  u  m  o
A  resistência  à insulina  contribui  para  a  ﬁsiopatologia  da diabetes  e é uma  característica  marcante  da
obesidade,  da síndrome  metabólica,  e de  doenc¸ as cardiovasculares.  Assim,  quantiﬁcar  a sensibilidade  à
insulina  vs  resistência  à  insulina  em  humanos  e em  modelos  animais  é de grande  importância.
Existem  vários  métodos  para  avaliar  a  sensibilidade  à  insulina,  tanto  em  indivíduos,  como  em
populac¸ ões  de  estudo.  A validade,  reprodutibilidade,  custo  e envolvimento  dos  indivíduos  são  fatores
importantes  a considerar  para  os  clínicos  e investigadores  aquando  da escolha  de  um  determinado  método
de avaliac¸ ão  da  sensibilidade  e/ou  resistência  à  insulina.  Alguns  métodos  dependem  da  quantiﬁcac¸ ão dos
níveis de  glucose  e de  insulina  no estado  estacionário,  embora  outros  métodos  possam  ser  utilizados
no  estado  dinâmico.  Cada  um  destes  métodos  tem  vantagens  e limitac¸ ões  distintas.  Assim,  a  escolha  e
a aplicabilidade  correta  de  um  método  especíﬁco  depende  da natureza  dos  estudos  a serem  realizados.
O desenho  de  métodos  diretos  para  medir  a  sensibilidade  à insulina  in  vivo  é relativamente  complexo.
Existem  alguns  índices  simples  para  avaliar  a  sensibilidade  e/ou  resistência  à insulina,  que  resultam  da
 ões  davaliac¸ ão das concentrac¸
prandial  (estado  dinâmico).  Es
de avaliac¸ ão de  sensibilidade  e
um  dos  métodos.
© 2012  Sociedade  Portu
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E-mail address: rita.patarrao@fcm.unl.pt (R.S. Patarrão).
646-3439/$  –  see  front  matter  ©  2012  Sociedade  Portuguesa  de  Endocrinologia,  Diabete
ttp://dx.doi.org/10.1016/j.rpedm.2013.10.004e  insulina  e glucose  em  jejum  (estado  estacionário)  ou  no  estado  pós-
te  artigo  destaca  as  limitac¸ ões  e a utilizac¸ ão  adequada  dos  atuais  métodos
/ou  resistência  à insulina  e apresenta  as vantagens  e desvantagens  de cada
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Measurements of insulin sensitivity provide clinicians and
esearchers with excellent instruments to objectively evaluate the
fﬁciency of both current and potentially useful interventional
ools.
It is of great importance to develop tools for quantifying insulin
ensitivity/resistance in humans, which may  be used to appropri-
tely investigate the epidemiology, pathophysiologic mechanisms,
utcomes of therapeutic interventions, and clinical course of
atients with insulin resistance.
ethods of insulin sensitivity/resistance assessment
yperinsulinemic Euglycemic Glucose Clamp
The Hyperinsulinemic Euglycemic Clamp (HIEC), originally
eveloped by DeFronzo, is widely accepted as the “gold standard”
or directly determining metabolic insulin sensitivity in humans.1
fter an overnight fast, insulin is infused intravenously at a con-
tant rate that may  range from 5 to 120 mU/m2/min (dose per body
urface area per minute, during 180 min). This constant insulin
nfusion results in a new steady-state insulin level that is above the
asting level (hyperinsulinemic). Consequently, glucose disposal
n skeletal muscle and adipose tissue is increased while hepatic
lucose production (HGP) is suppressed. Under these conditions,
 glucose analyzer is used to frequently monitor blood glucose lev-
ls at 5–10 min  intervals, while 20% dextrose is given intravenously
t a variable rate in order to “clamp” blood glucose concentrations
n the normal range (euglycemic). After several hours of constant
nsulin infusion, steady-state conditions are typically achieved
or plasma insulin, blood glucose, and the glucose infusion rate
GIR). Assuming that the hyperinsulinemic state is sufﬁcient to
ompletely suppress HGP, and since there is no net change in blood
lucose concentrations under steady-state clamp conditions, the
IR must be equal to the glucose disposal rate (M). Thus, whole
ody glucose disposal at a given level of hyperinsulinemia can
e directly determined. M is typically normalized to body weight
r fat-free mass to generate an estimate of insulin sensitivity.
lternatively, an insulin sensitivity index (SI) derived from clamp
ata can be deﬁned as SIClamp = MG×I , where M is normalized for
 (steady-state blood glucose concentration) and I  (difference
etween fasting and steady-state plasma insulin concentrations).2
The validity of glucose clamp measurements of insulin sensitiv-
ty depends on achieving steady-state conditions. “Steady-state” is
ften deﬁned as a period greater than 30 min  (at least 1 h after initi-
tion of insulin infusion) during which the coefﬁcients of variation
or blood glucose, plasma insulin, and GIR are less than 5%.2 It is
ossible to use a radiolabeled glucose tracer under clamp condi-
ions to estimate hepatic glucose production, so that appropriate
orrections can be made to M in the event HGP is not completely
uppressed.3–5 An alternative approach is to use an insulin infusion
ate sufﬁciently high to completely suppress HGP according to the
nsulin sensitivity/resistance of the population to be studied.
M is routinely obtained at only a single insulin infusion rate,
nd therefore comparisons between M or SIClamp among different
ubjects is valid only if the same insulin infusion rate is used for
ll subjects.
The principal advantage of the glucose clamp in humans is
hat it directly measures whole body glucose disposal at a given
evel of insulinemia under steady-state conditions. Conceptually,
he approach is straightforward but there is a limited number of
ssumptions that are clearly deﬁned. In research settings where
ssessing insulin sensitivity/resistance is of primary interest andDiabetes Metab. 2014;9(1):65–73
feasibility is not an issue, it is appropriate to use the glucose clamp
technique.
The main limitations of the HIEC approach are that it is time-
consuming, labor intensive, expensive, and requires an experienced
operator to manage technical difﬁculties. Another limitation is
that the clamp utilizes steady-state insulin levels that may  be
supraphysiological. This results in a reversal of the normal por-
tal to peripheral insulin gradient. Thus, the glucose clamp may
not accurately reﬂect insulin action and glucose dynamics under
physiological conditions that a dynamic test, such as, an oral meal
or oral glucose load may  determine. Further, in the HIEC insulin
sensitivity is measured only under a steady-state condition, and
therefore, the test does not realistically portray dynamic condi-
tions such as those occurring after normal meals. Because HIEC is
dependent on steady-state conditions, insulin infusion is continu-
ous for ≈3 h, and the subjects are in the fasted state. The results of
the HIEC may  be limited by these restraints, because insulin release
is pulsatile,6–8 and insulin action is sensitized in the postprandial
state.9 Nevertheless, it should be remembered that the HIEC meas-
ures insulin-stimulated glucose disposal only at insulin levels in
the upper physiological range; information on the effects of insulin
on glucose uptake and production in the basal condition, which is
physiologically very important, is not provided (unless tracers are
used).10
Insulin Tolerance Test
The Insulin Tolerance Test (ITT) was  one of the ﬁrst methods
developed to assess insulin sensitivity in vivo.11 In this method,
a ﬁxed bolus of regular insulin (0.1 IU/kg bw) is given iv after an
8–10 h fast. Blood samples are collected at 15 and 5 min  before and
3, 6, 9, 12, 15, 20 and 30 min  after insulin injection, and the plasma
glucose decrement is then measured. Glucose is injected at 30 min
to stop the fall in plasma glucose.12,13 The faster the decline in glu-
cose concentration, the more insulin sensitive the subject is. The
slope of the linear decline in plasma glucose (KITT) can be calcu-
lated by dividing 0.693 by the plasma glucose half-time (50% from
baseline):
KITT =
0.693
t1/2
× 100
where t1/2 represents the half-life of plasma glucose decrease, and
is calculated from the slope of least square analysis of the plasma
glucose concentrations from 3 to 15 min  after iv insulin injection,
when the plasma glucose concentration declined linearly. Normal
KITT is >2.0%/min and values <1.5%/min are considered abnormal.
This method gives an indirect estimate of overall insulin sensitivity.
The advantages of the ITT include its simplicity, rapidity and
the use of a bolus injection of insulin. The bolus injection of insulin
mimics the physiological pulsatile release of insulin.6 Furthermore,
because glucose tolerance after a meal is dependent on insulin
sensitivity, measuring insulin sensitivity in the prandial state is
physiologically relevant.
Some of the drawbacks of this method include the supraphys-
iological insulin dose used, and also the fact that the test does
not differentiate peripheral vs hepatic insulin resistance.14 Another
major limitation of this test is the risk of hypoglycemia. Hypo-
glycemia triggers hormonal responses, which may interfere with
insulin sensitivity and in turn slows the disappearance rate of
glucose from plasma.15 In this view, the fall in plasma glucose con-
centration would be a function of the interplay between insulin, on
the one hand, and glucagon, catecholamines, growth hormone and
cortisol, on the other. Given that, the counterregulatory response
occurs only 15–20 min  after insulin injection. The glucose fall occur-
ring in the ﬁrst 15 min  after iv insulin administration is probably a
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unction of insulin-stimulated glucose uptake by tissues as well as
nsulin ability to suppress glucose output by the liver.16
A lower insulin dose method of 0.05 IU/kg bw,  or shortening
he test to 15 min  was suggested as an attempt to decrease the risk
f hypoglycemia.14,17 The shorter version12,16 derived from the
otion that the counterregulatory hormone response occurs only
fter 20 min  of the insulin infusion.18
The ITT has been shown to correlate with the HIEC in several
tudies.12,16 However, arterialization of blood is essential in the
TT, as data from standard venous blood measurements showed no
igniﬁcant relationship with HIEC-derived glucose disposal.16
In conclusion, the ITT should be used with great caution in
nsulin sensitive individuals because of the increased risk of hypo-
lycemia, even when the smaller dose version of the test is used.
he shorter ITT is a valid test in large-scale studies, especially when
he site of resistance is not of importance.
nsulin Suppression Test
The insulin-suppression test (IST), another method that directly
easures metabolic insulin sensitivity/resistance, was introduced
y Shen et al. in 1970 and subsequently modiﬁed by Harano
t al.19,20 After an overnight fast, somatostatin (250 g/h) or
he somatostatin analog octreotide (25 g bolus, followed by
.5 g/min)21 is intravenously infused, to suppress endoge-
ous secretion of insulin and glucagon. Simultaneously, insulin
25 mU/m2/min) and glucose (240 mg/m2/min) are intravenously
nfused over 3 h. Blood samples for glucose and insulin determina-
ions are taken every 30 min  for 2.5 h, and then at 10 min  intervals
rom 150 to 180 min  of the IST. The constant infusions of insulin
nd glucose determine steady-state plasma insulin (SSPI) and glu-
ose (SSPG) concentrations. The steady-state period is assumed to
e from 150 to 180 min  after initiation of the IST. SSPI concen-
rations are generally similar among subjects. Therefore, the SSPG
oncentration will be higher in insulin resistant subjects and lower
n insulin sensitive subjects, i.e.,  SSPG values are inversely related
o insulin sensitivity. The IST provides a direct measure (through
SPG) of the ability of exogenous insulin to mediate disposal of an
v glucose load, under steady-state conditions, where endogenous
nsulin secretion is suppressed.22
The SSPG is a highly reproducible direct measure of metabolic
ctions of insulin, that is, less labor intensive and less technically
emanding than HIEC. Indeed, since there are no variable infusions
ith the IST, steady-state conditions are more easily achieved with
he IST than with HIEC. In research settings, the IST can be used
or larger populations that may  pose difﬁculties for application of
IEC. ELIMINAR esta frase.
Many of the limitations of the IST are similar to those described
or HIEC (with the exception that the IST is less technically demand-
ng). Thus, it is impractical to apply the IST in large epidemiological
tudies or in the clinical care setting. SSPG under ideal conditions
etermines primarily skeletal muscle insulin sensitivity, and is not
esigned to reﬂect hepatic insulin sensitivity.22
ontinuous infusion of glucose with model assessment
The continuous infusion of glucose with model assessment
CIGMA) is a procedure that assesses insulin sensitivity through
he evaluation of the near steady-state glucose and insulin con-
entrations after a continuous infusion of glucose, with model
ssessment.23 This method mimics postprandial glucose and
nsulin concentrations. CIGMA not only provides information about
lucose tolerance and insulin sensitivity, but also about -cell func-
ion. Using a mathematic model of glucose homeostasis, glucose
nd insulin values are compared with known physiologic data of
lucose, and insulin kinetics in response to glucose infusion, whichDiabetes Metab. 2014;9(1):65–73 67
are derived from healthy lean subjects with no family history of
diabetes.23
The glucose and insulin values used for CIGMA are obtained dur-
ing the last 15 min  of the 60 min  continuous glucose infusion (5 mg
glucose/kg bw/min). Samples are collected at 5 min  intervals and
the average is then compared with predicted values from the com-
puter model. The median value for normal subjects is 1.35, and for
diabetic patients with mild hyperglycemia is 4.0.23
There are two  main advantages of CIGMA over Homeostasis
Model Assessment (HOMA). First, the insulin values that are mea-
sured in CIGMA are much higher than those in HOMA owing to
the glucose stimulus and second, higher insulin concentration in
CIGMA stimulates peripheral glucose uptake producing a steady-
state glucose concentration, which is a better reﬂection of the
peripheral insulin sensitivity.18
Although CIGMA is more practical, cheaper and less invasive
than the frequently sampled intravenous glucose tolerance test
(FSIVGTT) and HIEC procedure, the model incorrectly assumes that
levels of insulin resistance at the liver and peripheral tissues are
equal. Furthermore, in insulin-deﬁcient subjects, where the insulin
response is insufﬁcient to stimulate glucose uptake, the interpre-
tation of CIGMA is difﬁcult.
Minimal model analysis of frequently sampled intravenous
glucose tolerance test
The minimal model, developed by Bergman, Cobelli and col-
leagues in 1979, provides an indirect measure of metabolic insulin
sensitivity/resistance based on glucose and insulin data obtained
during a frequently sampled intravenous glucose tolerance test
(FSIVGTT).24 After an overnight fast, an intravenous bolus of glucose
(0.3 g/kg bw) is infused over 2 min  starting at time 0.
Currently, a modiﬁed FSIVGTT is used, where exogenous insulin
(4 mU/kg/min) is also infused over 5 min  beginning 20 min after
the iv glucose bolus.25,26 Some studies use tolbutamide (a potas-
sium channel blocker) instead of insulin in the modiﬁed FSIVGTT,
to stimulate endogenous insulin secretion.27,28
Blood samples are taken for plasma glucose and insulin
measurements at different time points, before and 180 min
after glucose infusion. The data obtained are then subjected to
minimal model analysis using the computer program MINMOD
(minimal model approach – MINMOD), to generate an index of
insulin sensitivity (SI).
The MINMOD is deﬁned by two  coupled differential equations
with four model parameters (Fig. 1). The ﬁrst equation describes
plasma glucose dynamics in a single compartment. The second
equation describes insulin dynamics in a “remote compartment”.
The structure of the MINMOD allows it to uniquely identify model
parameters, which determine a best ﬁt to glucose disappearance
during the modiﬁed FSIVGTT. SI is calculated from two  of these
model parameters, and is deﬁned as fractional glucose disappear-
ance per insulin concentration unit.29
In addition to SI, other minimal model parameters may be used
to estimate a “glucose effectiveness” index (SG). SG is deﬁned as the
ability of glucose per se to promote its own  disposal and inhibit
hepatic glucose production (HGP) in the absence of an incremental
insulin effect (i.e., when insulin is at basal levels).
dG(t)
dt
= −[p1 + X(t)]G(t) + p1Gb (1)
dX(t)
dt
= −p2X(t) + p3[I(t) − ib] (2)Minimal model analysis of the modiﬁed FSIVGTT is easier than
HIEC method because it is slightly less labor intensive, steady-
state conditions are not required, and there are no iv infusions that
require constant adjustment. Unlike HIEC or IST, information about
68 R.S. Patarrão et al. / Rev Port Endocrinol 
Liver
Glucose space
Glucose Disposal
Skeletal muscle
Remote insulin
compartmentPlasna insulin I(t)
Glucose production
Fig. 1. Schematic equations and parameters for the minimal model of glucose
metabolism. Differential equations describing glucose dynamics [G(t)] in a mono-
compartmental “glucose space” and insulin dynamics in a “remote compartment”
[X(t)] are shown at the top. Glucose leaves or enters its space at a rate proportional
to  the difference between plasma glucose level, G(t) and the basal fasting level, Gb .
In  addition, glucose also disappears from its compartment at a rate proportional
to  insulin levels in the “remote” compartment [X(t)]. In this model, t – time; G(t)
–  plasma glucose at time t; I(t) – plasma insulin concentration at time t; X(t) –
insulin concentration in “remote” compartment at time t; Gb – basal plasma glucose
concentration; Ib – basal plasma insulin concentration; G(0) – G0 (assuming instan-
taneous mixing of the iv glucose load); p1, p2, p3 and G0 – unknown parameters in
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ghe  model that are uniquely identiﬁable from FSIVGTT; glucose effectiveness (SG) –
1 and insulin sensitivity – p3/p2.
dapted from Ref. 29.
nsulin sensitivity, glucose effectiveness, and -cell function can be
erived from a single dynamic test. The minimal model generates
xcellent predictions of glucose disappearance during the FSIVGTT.
In research settings, where assessing insulin sensitivity along
ith glucose effectiveness and -cell function is of interest, min-
mal model analysis of the insulin-modiﬁed FSIVGTT may  be
ppropriate. The minimal model approach is simpler than direct
ethods for determining insulin sensitivity. Nevertheless, it still
nvolves iv infusions with multiple blood sampling over a 3 h
eriod, that is, nearly as labor intensive as the HIEC or IST. In
ddition, many limitations of minimal model analysis stem from
he fact that the model oversimpliﬁes the physiology of glucose
omeostasis.29
Another oversimpliﬁcation of the minimal model involves
umping together effects of insulin to promote peripheral glu-
ose utilization and suppress HGP. As insulin sensitivity/resistance
aries, the relative contribution of HGP to SI may  vary signiﬁcantly.
ince the minimal model relies on a dynamic test to evaluate insulin
ensitivity, estimates of SI are much less reliable in individuals
ith impaired insulin secretion and/or signiﬁcant insulin resistance
when compared with healthy subjects). Under these conditions,
he minimal model may  overestimate SG to accurately predict the
isappearance of glucose during the FSIVGTT. Indeed, estimates
f SG are spuriously affected by differences in insulin secretory
apacity.26,30 Moreover, for similar reasons, minimal model analy-
is often generates senseless negative values for SI in a substantial
roportion of subjects with diabetes, who have minimal insulin
ecretory capacity and signiﬁcant insulin resistance.2,30 These non-
ystematic errors inherent in the minimal model approach are
ighlighted by calibration model analysis, demonstrating that some
imple surrogate indexes of insulin sensitivity have better abso-
ute accuracy for predicting SIClamp than the minimal model-derived
I.31
ral Glucose Tolerance Test
The Oral Glucose Tolerance Test (OGTT) is a simple test, widely
sed in clinical practice to diagnose glucose intolerance and type
 diabetes.18,32,33 After an overnight fast, blood samples for deter-
inations of glucose and insulin concentrations are taken at 0, 30,
0, and 120 min  following a standard oral glucose load (75 g).33
 diagnosis of diabetes is conferred if an individual has a plasma
lucose level ≥200 mg/dl (11 mmol/l) as measured 2 h after theDiabetes Metab. 2014;9(1):65–73
ingestion of a 75 g glucose load. If an individual has a value in
the range of 140–199 mg/dl (7.7–11 mmol/l) 2 h post-glucose load,
it is designated as having impaired glucose tolerance.33 Oral glu-
cose tolerance reﬂects the efﬁciency with which the body handles
glucose after an oral glucose load.
The OGTT mimics the glucose and insulin dynamics of physio-
logical conditions more closely than conditions of the HIEC, IST or
frequently sample intravenous glucose tolerance test (FSIVGTT).34
However, it is important to recognize that glucose tolerance and
insulin sensitivity are not equivalent concepts. In addition to
metabolic actions of insulin, insulin secretion, incretin effects, and
other factors contribute importantly to glucose tolerance. Thus, the
OGTT, by itself, provides useful information about glucose tolerance
but not insulin sensitivity/resistance per se.35,36 During the OGTT,
the use of a glucose tracer and both insulin and C-peptide plasma
measurements at speciﬁc time points, allows the calculation of glu-
cose clearance.
The OGTT is technically quite simple to perform and certainly
lower in cost than HIEC or FSIVGTT. These considerations have
made the OGTT the glucose challenge test of choice in clinical
situations.37 However, there are some problems with the OGTT that
make it less desirable for use in research situations. First, there is
variability in the rate of gastric emptying and glucose absorption
from the gastrointestinal tract, causing some imprecision from the
start. This variability can partially account for poorly reproducible
results even within the same individual.38 Second, glucose mea-
surements in the standard OGTT do not give adequate information
regarding the dynamics of glucose and insulin action.33
The OGTT is a relatively crude measure of glucose tolerance. It
does not measure the components of insulin sensitivity and insulin
secretion. In light of this limitation, attempts have been made to
obtain indices from OGTT data that might better reﬂect -cell func-
tion and insulin sensitivity.39,40
Meal Tolerance Test
In an attempt to study the ability to regulate blood glucose in a
more physiological situation than the OGTT, some authors measure
the glycemic proﬁle in response to the ingestion of a mixed meal
containing carbohydrates, fat and proteins; the Meal Tolerance Test
(MTT).
The experimental procedure for the MTT  is similar to the OGTT,
that is, after an overnight fast (10–12 h), a mixed meal (liquid or
solid) is given and the glycemic proﬁle is measured throughout
2 h; usually the insulin proﬁle is also determined during the same
period of time.34,36
The MTT  is a “physiologic” variant of OGTT41 offering sev-
eral advantages: (a) lack of artifactual postload hypoglycemia,
thus making this test suitable for the study of postprandial hypo-
glycemia, a situation which is frequently due to high values of
insulin sensitivity, but also to hyperinsulinism in a context
of insulin resistance42; (b) use of a physiologic stimulus triggering a
cephalic phase proportional to palatability scores43; (c) possibility
to measure insulin sensitivity with a modiﬁed algorithm based on
the minimal model36 as well as glucose effectiveness and insulin
secretion; (d) potential for evaluating the physiologic effects of
incretins.44
The MTT  can represent a simple procedure, less unpleasant for
the patient than the standard OGTT, and providing both a physi-
ologic picture of glucoregulation, and a sophisticated and precise
analysis of this glucoregulation, in terms of insulin sensitivity, glu-
cose effectiveness, and insulin secretion.41
The -cell response is stronger after a mixed meal than after
an OGTT with equal carbohydrate quantity, both for classical
and model-based parameters. The higher response was  mostly
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xplained by higher -cell sensitivity during the meal, which may
ead to lower glucose excursions.45
Several factors may  contribute to differences in insulin secretion
ollowing an MTT  compared with the OGTT. The MTT has a lower
lycemic index than the OGTT, which may  lead to lower glucose
xcursions.46 Moreover, slower gastric emptying following the MTT
ue to larger volume,47 solid character,48 and fat content49 will lead
o a slower entry of nutrients into the circulation.
The MTT  might be considered as an additional tool for the
ssessment of metabolic abnormalities, in glucose-intolerant and
nsulin-resistant states.34
Thus, the MTT  is a more physiological test than the OGTT, in
egard to human diet, and is potentially able to give useful infor-
ation concerning islet -cell function in the different categories
f glucose intolerance,50 but not insulin sensitivity/resistance per
e.36
As any other method that measures glucose tolerance, the MTT
oes not assess insulin sensitivity directly and may  not be repeated
n the same subject or animal on the same day.
apid Insulin Sensitivity Test
A new method for insulin sensitivity quantiﬁcation, called the
apid Insulin Sensitivity Test (RIST), was described and evaluated
or use in rats,51,52 cats53,54 mice55 and humans.56 The standard
ynamic proﬁle for the RIST in fed and fasted humans as well as
he RIST insulin sensitivity index is shown in Fig. 2.
The RIST is an euglycemic test and is carried out after estab-
ishing the glycemic baseline, which is done by taking arterialized
enous blood samples at 5 min  intervals until three consecu-
ive measurements are stable. An insulin infusion is commenced
50 mIU/kg administered over 5 min) and, after 1 min, glucose
amples are taken at 2 min  intervals, and glucose is infused intra-
enously at a variable rate to maintain euglycemia. The test is
ompleted when no more glucose is required. At the standard test
ose of insulin of 50 mIU/kg, the RIST in the fasted state is com-
lete within approximately 40 min. The RIST index, the insulin
ensitivity parameter, is simply the amount of glucose that had to
e administered in order to maintain euglycemia after the bolus
dministration of insulin.52
The majority of the insulin sensitivity tests are done in the
asted state, when insulin sensitivity would be logically antici-
ated to be at its lowest level. Studies performed by Patarrão
t al. and Lautt et al. indicated that the fasted state results in a
ery low insulin responsiveness. It is reasonable that insulin sensi-
ivity should be under a regulatory mechanism such that in the
asted state insulin effect would be minimized, and inappropri-
te release of insulin would not, therefore, lead to life-threatening
ypoglycemia. The RIST can be carried out in the fed state.9,56 Fur-
hermore, the RIST allows insulin sensitivity assessment before and
fter a meal, making it possible to test both meal and drug effects
n insulin sensitivity.56,57
The RIST is extremely sensitive and can be shown to generate
ose-response relationships to insulin, which makes the RIST the
ost advantageous method in the determination of small differ-
nces in insulin sensitivity. This method is able to be carried out
ore than one time in the same subject with high reproducibility,
nd is sufﬁciently versatile to permit paired experimental designs,
n the same subjects and on the same day. Both the accuracy and
recision of the test can be assessed from determination of the
eviation from the ideal euglycemic target.52
Insulin release normally occurs in a pulsatile manner, and
ormones released in a pulsatile manner are best studied by pul-
atile administration.58 Based on this assumption, the intravenous
nsulin bolus administered at the beginning of the RIST mimics the
hysiological insulin action. It also avoids the vagal withdrawalDiabetes Metab. 2014;9(1):65–73 69
and sympathetic activation induced by sustained hyperinsuline-
mia, during the HIEC55,59 and the hypoglycemia caused by the
acute ITT.59 It does not alter levels of counter-regulatory hormones,
such as catecholamines, somatostatin or glucagon.54 Moreover,
both insulinemia and glycemia return to basal levels after each
RIST.
One methodological issue relates to the basal glucose concen-
tration determined before and after the RIST. Previous studies
demonstrate clearly that there is no mean change in basal blood
glucose levels used as the euglycemic target when, for example,
compared before and after denervation of the hepatic plexus in
rats60 or atropine.61 In addition, we have also determined that there
is no correlation between the magnitude of the RIST index and
basal glucose levels when compared using a large number of data
points.52 Of more concern is the importance that glucose uptake
or output should not change during the RIST. Whatever stimu-
lus is used, including either ablation or stimulation protocols, the
stimulus is administered prior to conducting the RIST, and a new
stable glycemic baseline must be demonstrated. In addition, at the
conclusion of the RIST index, the re-established baseline must not
be signiﬁcantly altered. In the event that such alteration occurs, it
suggests that glucose output either increased or decreased during
the test. This is usually obvious by comparing the shape of normal
RIST curves with that obtained in the presence of the altered base-
line. In such situations, the data must be excluded, and the RIST
repeated.
None of the available methods available to estimate insulin sen-
sitivity/resistance proved to be a reliable way to assess insulin
sensitivity/resistance since most of them have non-physiological
continuous infusion of insulin and/or glucose, which interfere with
peripheral insulin sensitivity/resistance; take a long time to be
performed; could not avoid counter-regulatory responses to the
hypoglycemia that follows an insulin bolus; could not allow
the assessment of insulin sensitivity in different conditions in the
same subject, and in the same day; and they only evaluate insulin
sensitivity/resistance in the fasted state. Based on all of these draw-
backs, it was  necessary to develop another method for assessing
insulin sensitivity/resistance.
To summarize, the RIST is a quick method to evaluate insulin
sensitivity, reproducible in the same subject and on the same day,
utilizes a bolus of insulin to mimic  pulsatile insulin release, and can
be performed in the fed or fasting state. In addition, since the RIST
is an euglycemic test, avoids hypoglycemia and prevents the acti-
vation of counter-regulatory hormones. The RIST provides a new
powerful tool to dissect insulin action in the fasted and fed state,
and may  provide a means to detect the pre-diabetic state, where
early insulin resistance can be detected well before the impairment
of the direct effect of insulin at a time when lifestyle interventions
can be readily tested.
Simple surrogate indexes for insulin sensitivity/resistance
Homeostasis Model Assessment
The Homeostasis Model Assessment (HOMA), developed in
1985, is a model of interactions between glucose and insulin
dynamics, that is then used to predict fasting steady-state glucose
and insulin concentrations, for a wide range of possible combina-
tions of insulin resistance and -cell function.62 The model assumes
a feedback loop between the liver and -cell62,63; and glucose con-
centrations are regulated by insulin-dependent hepatic glucose
production, while insulin levels depend on the pancreatic -cell
response to glucose concentrations. Thus, a diminished response
to glucose-stimulated insulin secretion reﬂects deﬁcient -cell
function. Likewise, insulin resistance is reﬂected by diminished
suppressive effect of insulin on hepatic glucose production.
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Fig. 2. (A) Mean proﬁle using the dynamic analysis of the pattern of glucose infusion during the Rapid Insulin Sensitivity Test (RIST). The mean RIST curves were obtained
by  averaging glucose infusion rates at 0.1-min intervals throughout the test (Postprandial RIST (bold line) and the RIST obtained after 24 h-fast (simple line)). (B) Calculation
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df  the area under the curve during the 24 h-fast and postprandial RIST, that corresp
hich is terminated when no further glucose infusion is required (RIST index).56
HOMA model describes this glucose-insulin homeostasis by a
et of empirically derived non-linear equations. The model pre-
icts fasting steady-state levels of plasma glucose and insulin for
ny given combination of pancreatic -cell function (HOMA%B) and
nsulin sensitivity (HOMA%S).
In practical terms, most studies using HOMA employ an approx-
mation described by a simple equation to determine a surrogate
ndex of insulin resistance. This is deﬁned by the product of the fas-
ing glucose and fasting insulin, divided by a constant. The formula
or the HOMA model is:
OMA = Fasting Insulin (IU/ml) × Fasting Glucose (mmol/l)
22.5
The denominator of 22.5 is a normalizing factor, i.e.,  the product
f normal fasting plasma insulin of 5 IU/ml and normal fas-
ing plasma glucose of 4.5 mmol/l obtained from an “ideal and
ormal” individual.62 Therefore, for an individual with normal
nsulin sensitivity, HOMA = 1. It is important to note that, over
ide ranges of insulin sensitivity/resistance, log (HOMA) trans-
orms the skewed distribution of fasting insulin values to determine
 much stronger linear correlation with HIEC estimates of insulin
ensitivity.2
HOMA or log (HOMA) is extensively used in large epidemio-
ogical studies, prospective clinical trials, and research studies. In
esearch settings where assessing insulin sensitivity/resistance is
f secondary interest or feasibility issues preclude the use of direct
easures by HIEC, it may  be appropriate to use log (HOMA).63
uantitative insulin sensitivity check index
Quantitative insulin sensitivity check index (QUICKI) is an
mpirically derived mathematical transformation that uses fasting
lood glucose and plasma insulin concentrations. It provides a
eliable, reproducible, and accurate index of insulin sensitivity
ith excellent positive predictive power.2,64 Since fasting insulin
evels have a non-normal skewed distribution, log transformation
mproves its linear correlation with reference standard glucose
lamp (SIClamp). However, as with 1/(fasting insulin) and the
lucose/insulin ratio, this correlation is not maintained in diabetic
ubjects with fasting hyperglycemia and impaired -cell function
hat is insufﬁcient to maintain euglycemia. To accommodate
hese clinically important circumstances where fasting glucose is
nappropriately high, insulin is inappropriately low, application of
ogarithm to both fasting glucose, and fasting insulin provides a
easonable correction such that the linear correlation with SIClamp
s maintained, in both diabetic and non-diabetic subjects. The
eciprocal of this sum results in further transformation of the
ata generating an insulin sensitivity index that has a positiveo the total amount of glucose infused to maintain euglycemia over the test period,
correlation with SIClamp. Thus, QUICKI is deﬁned by the following
formula:
QUICKI
= 1
log(fasting insulin, IU/ml) + log (fasting glucose, mg/dl)
QUICKI is among the most thoroughly evaluated and validated
surrogate index for insulin sensitivity. As a simple, useful, inexpen-
sive, and minimally invasive surrogate for HIEC-derived measures
of insulin sensitivity, QUICKI is appropriate and effective for use in
large epidemiological or clinical research studies, to follow changes
after therapeutic interventions, and for use in studies where eval-
uation of insulin sensitivity is not of primary interest.2,65
QUICKI and HOMA were derived in a completely different
conceptual fashion. Nevertheless, these two  surrogate indexes
are mathematically related, i.e.,  QUICKI is proportional to 1/log
(HOMA).
The major advantage of both the QUICKI and HOMA models is
that they both require only one blood draw from a fasting patient.
They thus do not require extensive technical expertise, and con-
stitute a much lower cost per subject when compared with the
HIEC or the FSIVGTT, making the QUICKI and HOMA models much
more practical for use in large-scale epidemiologic studies, and for
clinical situations.63
However, the major disadvantage is that both of these methods
fail to provide information about the stimulated glucose and insulin
systems. Essentially, they provide information only about what is
occurring with homeostatic mechanisms in the fasting state, largely
reﬂecting insulin’s effect on hepatic glucose production and not
on peripheral glucose uptake, which is the more relevant aspect
concerning insulin action/resistance.
Insulin sensitivity indexes
Cederholm and Wibell index
The insulin sensitivity index proposed by Cederholm and Wibell
represents mainly peripheral insulin sensitivity and muscular glu-
cose uptake, due to the dominant role of peripheral tissues in
glucose disposal after an oral glucose load.40
The formula for the Cederholm index is:
ISICederholm =
75000 + (G0 − G120) × 1.15 × 180 × 0.19 × m
120 × Gmean × log(Imean)
where 75,000 – oral glucose load in an OGTT in mg,  G0 – fas-
ting plasma glucose concentration (mmol/l), G120 – plasma glucose
concentration in the 120th min  of OGTT (mmol/l), 1.15 – fac-
tor transforming whole venous blood glucose to plasma values
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not necessary, if glucose concentration is estimated in plasma),
80 – conversion factor to transform plasma glucose concentration
rom mmol/l into mg/dl, 0.19 – glucose space in liter per kg of body
eight, m – body weight (kg), 120 – duration of OGTT (min), Imean –
ean plasma insulin concentration during OGTT (mIU/l) and Gmean
 mean plasma glucose concentration during OGTT (mmol/l).
Values found in normal non-obese individuals were reported to
e about 79 ± 14 mg  l2/mmol/mIU/min, lower in obese individuals,
n subjects with impaired glucose tolerance and in patients with
ype 2 diabetes.40
utt et al. index
The ISI0,120 was adapted from the Cederholm insulin sensitivity
ndex, by omitting the constant terms, and using the plasma glucose
nd insulin concentration from fasting (0 min) and 120 min  samples
rom the OGTT.66
The ISI0,120 index is deﬁned as:
SI0,120 =
75,  000 + (G0 − G120) × 0.19 × m
120 × Gmean × log(Imean)
here 75,000 – oral glucose load in an OGTT in mg,  G0 – fasting
lasma glucose concentration (mg/dl), G120 – plasma glucose con-
entration in the 120th min  of OGTT (mg/dl), 0.19 – glucose space in
/kg of body weight, m – body weight (kg), 120 – duration of OGTT
min), Imean – mean plasma insulin concentration during OGTT
mIU/l) and Gmean – mean plasma glucose concentration during
GTT (mmol/l).
The reference range for lean controls was 89 ± 39, for obese
8 ± 23 and for diabetic patients 23 ± 19 mg  l2/mmol/mIU/min.18
vignon et al. index
Avignon67 proposed 3 insulin sensitivity indices: Sib (derived
rom fasting plasma insulin and glucose concentrations), Si2h
derived from plasma insulin and glucose concentrations in the
20th min  of OGTT) and SiM (derived by averaging Sib and Si2h
fter balancing Sib by a coefﬁcient of 0.137 to give the same weight
o both indices):
ib = 10
8
I0 × G0 × VD
Si2h = 10
8
I120 × G120 × VD
SiM = (0.137 × Sib) + Si2h
2
here I and G represent the plasma concentrations of insulin
mIU/l) and glucose (mmol/l), respectively and, VD is the glu-
ose distribution volume calculated using a monocompartmental
odel: VD = 150 ml/kg of body weight.28
atsuda et al. index
Originally proposed by Matsuda and DeFronzo,39 insulin sen-
itivity index-Matsuda (ISI(Matsuda)) is an whole body insulin
ensitivity index that reﬂects a composite estimate of hepatic and
uscle insulin sensitivity. This index is calculated from plasma glu-
ose (mg/dl) and insulin (mIU/l) concentrations in fasting state and
uring OGTT.
The formula for the Matsuda index is:
SI(Matsuda) =
10, 000√
G0 × I0 × Gmean × Imean
here 10,000 – simplifying constant to get numbers from 0 to 12,
– correction of the nonlinear values distribution, G0 – fastinglasma glucose concentration (mg/dl), I0 – fasting plasma insulin
oncentration (mIU/l), Gmean – mean plasma glucose concentration
uring OGTT (mg/dl), from 0 to 120 min  and Imean – mean plasma
nsulin concentration during OGTT (mIU/l), from 0 to 120 min.Diabetes Metab. 2014;9(1):65–73 71
The insulin secretion/insulin resistance (disposition) index
calculated as the product of insulin secretion measured with
(I0–30/G0–30 or I0–120/G0–120) and ISI(Matsuda) (or modiﬁed
ISI(Matsuda) using plasma glucose and insulin concentrations at
30 min  during the OGTT), had excellent power to predict onset of
type 2 diabetes.68
Belﬁore et al. index
The condition for calculation of the Belﬁore formula is the
deﬁnition of the normal value for basal glucose and insulin concen-
trations, and for mean normal value for glucose and insulin areas
during OGTT.18 The main point of the Belﬁore formula is the com-
parison of insulin and glucose values measured (fasting, 0–1–2 h
areas or 0–2 h areas) with the deﬁned normal reference values.
The ISIBelﬁore index is deﬁned as:
ISIBelﬁore =
2
(GS/GN) × (IS/IN) + 1
where Gs, GN – plasma glucose concentrations expressed as fasting
values or as areas obtained during a standard OGTT at 0 and 2 h
(0–2 h areas are equal to GS,N = G0 + G120) or at 0, 1 and 2 h (0–1–2 h
areas equal to GS,N = ½G0 + G60 + G120, Is, IN – plasma insulin concen-
trations expressed as fasting values or as areas obtained during a
standard OGTT at 0 and 2 h (0–2 h areas are equal to IS,N = I0 + I120) or
at 0, 1 and 2 h (0–1–2 h areas equal to IS,N = ½I0 + I60 + I120. The sub-
scripts S and N refer to “subjects” and “normal reference values”,
respectively.
Insulin sensitivity calculated using these formulas can achieve
only values between 0 and 2. In subjects with normal insulin sen-
sitivity is it around 1; in overweight subjects, in subjects with
impaired glucose tolerance, and with type 2 diabetes this value is
below 1.69,70
Stumvoll et al. index
Stumvoll proposed a series of indices calculated from plasma
glucose (mmol/l) and insulin (pmol/l concentrations during
OGTT).70 The equations were generated using the multiple linear
regression analysis and adapted to the availabilities of sampling
times during OGTT, and of demographic parameters (BMI, age).
An example equation could be the index of insulin sensitivity
calculated from data obtained in 0, 60 and 120 min  of OGTT either
with or without demographic data:
ISIStumvoll = 0.222 − 0.00333 × BMI  − 0.0000779 × I120
− 0.000422 × age
ISIStumvoll = 0.156 − 0.0000459 × I120 − 0.000321 × I0 −
0.00541 × G120
McAuley et al. index
The authors proposed a formula for predicting insulin resistance
in normoglycemic individuals.71 Regression analysis was used to
estimate the cut-off points and the importance of various data for
insulin resistance (fasting concentrations of insulin, triglycerides,
aspartate aminotransferase, BMI, waist circumference). A bootstrap
procedure was  used to ﬁnd an index most strongly correlating with
insulin sensitivity index, corrected for fat-free mass obtained by
HIEC
(
Mffm
I
)
.1
An insulin sensitivity index obtained from HIEC of ≤6.3
(expressed as glucose disposal rate in mg/kg/min divided by aver-
age plasma insulin concentration in mIU/l) was seen as a cut-off
for individuals with insulin resistance. The combination of fasting
insulin (mIU/l) and triglycerides (TAG, mmol/l) showed the best
prediction of insulin resistance as follows:
(
Mffm
I
)
= e2.63−0.28 ln (I0)−0.31 ln (TAG0)
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here I0 – fasting plasma insulin concentration (mIU/l) and TAG0
 fasting plasma triglycerides concentration (mmol/l).
ral Glucose Insulin Sensitivity
The Oral Glucose Insulin Sensitivity (OGIS) is a method for the
ssessment of insulin sensitivity from the OGTT. OGIS provides an
ndex that correlates to the index of insulin sensitivity obtained
rom the HIEC.
This method calculates insulin sensitivity with a model-derived
quation of the form:
GIS = f (G0, G90, G120, I0, I90, I120, DO)
here G and I are glucose and insulin concentrations (subscripts
epresent time instant) and DO is the oral glucose dose (g/m2 body
urface area).
The function f is complex, but can be easily programmed on
 spreadsheet (see http://www.isib.cnr.it/bioing/ogis/home.html,
here a web-based calculator is also available). The expression of
 contains some parameters, chosen to maximize the agreement
ith the HIEC. Glucose and insulin can be given in either com-
on or international units (with appropriate parameters, see table
 in72).
OGIS is a predictor of the HIEC insulin sensitivity, expressed
s glucose clearance M/G, normalized to body surface area. The
nits of OGIS are thus ml/min/m2 of body surface area. OGIS
as been validated against an 120 mU/min/m2 insulin infusion
IEC (by direct comparison of the glucose clearance values),
nstead of the more standard 40 mU/min/m2 used in the pre-
ious methods. Formulas for a 3 h and 2 h OGTT are also
vailable.72
OGIS exploits the known quantitative relationships between the
bserved data and the HIEC insulin sensitivity to attempt a genuine
nsulin sensitivity prediction. However, this advantage is limited
y the necessity to use empirical assumptions, and to calculate
arameters from regression.72
apid Insulin Sensitivity Test index
The RIST index is the parameter used to evaluate insulin sensi-
ivity that represents the total amount of glucose infused during
he Rapid Insulin Sensitivity Test (RIST), in order to maintain
uglycemia after the exogenous bolus administration of insulin.
t corresponds to the area under the curve (AUC) of total glucose
nfused (mg  glucose/kg bw)  throughout the test52:
IST Index = AUC of Glucose
onclusions
This paper has examined a wide variety of methods currently
vailable for estimating insulin sensitivity/resistance and also
ntroduces a new method – the RIST. The methods range from
omplex, time-consuming, labor-intensive, invasive procedures to
imple tests involving a single fasting blood sample. It is important
o understand the concepts underlying each method so that rela-
ive merits and limitations are appropriately matched to proposed
pplications. Developing valid, reliable, cost-effective methods of
ssessing insulin sensitivity is a major scientiﬁc challenge. Dynamic
ests are useful if information about both insulin secretion and
nsulin action are needed. As with all measurement techniques,
orrect interpretation of data from different methods for measur-
ng insulin sensitivity requires a complete understanding of the
echnique.
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